A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
Identifieur interne : 001812 ( Main/Exploration ); précédent : 001811; suivant : 001813A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
Auteurs : Steve P H. Alexander [Royaume-Uni] ; Jane F. Armstrong [Royaume-Uni] ; Anthony P. Davenport [Royaume-Uni] ; Jamie A. Davies [Royaume-Uni] ; Elena Faccenda [Royaume-Uni] ; Simon D. Harding [Royaume-Uni] ; Francesca Levi-Schaffer [Israël] ; Janet J. Maguire [Royaume-Uni] ; Adam J. Pawson [Royaume-Uni] ; Christopher Southan [Royaume-Uni, Suède] ; Michael Spedding [France]Source :
- British journal of pharmacology [ 1476-5381 ] ; 2020.
Abstract
In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.
DOI: 10.1111/bph.15094
PubMed: 32358833
PubMed Central: PMC7267163
Affiliations:
- France, Israël, Royaume-Uni, Suède
- Angleterre, Angleterre de l'Est, Nottinghamshire, Écosse
- Cambridge, Nottingham, Édimbourg
- Université d'Édimbourg, Université de Cambridge, Université de Nottingham
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.</title><author><name sortKey="Alexander, Steve P H" sort="Alexander, Steve P H" uniqKey="Alexander S" first="Steve P H" last="Alexander">Steve P H. Alexander</name><affiliation wicri:level="4"><nlm:affiliation>Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), School of Life Sciences, University of Nottingham, Nottingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), School of Life Sciences, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation></author><author><name sortKey="Armstrong, Jane F" sort="Armstrong, Jane F" uniqKey="Armstrong J" first="Jane F" last="Armstrong">Jane F. Armstrong</name><affiliation wicri:level="4"><nlm:affiliation>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Davenport, Anthony P" sort="Davenport, Anthony P" uniqKey="Davenport A" first="Anthony P" last="Davenport">Anthony P. Davenport</name><affiliation wicri:level="4"><nlm:affiliation>Executive Committee, NC-IUPHAR, University of Cambridge, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Executive Committee, NC-IUPHAR, University of Cambridge, Cambridge</wicri:regionArea><orgName type="university">Université de Cambridge</orgName><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName></affiliation></author><author><name sortKey="Davies, Jamie A" sort="Davies, Jamie A" uniqKey="Davies J" first="Jamie A" last="Davies">Jamie A. Davies</name><affiliation wicri:level="4"><nlm:affiliation>Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Faccenda, Elena" sort="Faccenda, Elena" uniqKey="Faccenda E" first="Elena" last="Faccenda">Elena Faccenda</name><affiliation wicri:level="4"><nlm:affiliation>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Harding, Simon D" sort="Harding, Simon D" uniqKey="Harding S" first="Simon D" last="Harding">Simon D. Harding</name><affiliation wicri:level="4"><nlm:affiliation>Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Levi Schaffer, Francesca" sort="Levi Schaffer, Francesca" uniqKey="Levi Schaffer F" first="Francesca" last="Levi-Schaffer">Francesca Levi-Schaffer</name><affiliation wicri:level="1"><nlm:affiliation>First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), Hebrew University of Jerusalem, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), Hebrew University of Jerusalem, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Maguire, Janet J" sort="Maguire, Janet J" uniqKey="Maguire J" first="Janet J" last="Maguire">Janet J. Maguire</name><affiliation wicri:level="4"><nlm:affiliation>University of Cambridge, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Cambridge, Cambridge</wicri:regionArea><orgName type="university">Université de Cambridge</orgName><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName></affiliation></author><author><name sortKey="Pawson, Adam J" sort="Pawson, Adam J" uniqKey="Pawson A" first="Adam J" last="Pawson">Adam J. Pawson</name><affiliation wicri:level="4"><nlm:affiliation>Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Southan, Christopher" sort="Southan, Christopher" uniqKey="Southan C" first="Christopher" last="Southan">Christopher Southan</name><affiliation wicri:level="4"><nlm:affiliation>Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>TW2Informatics Ltd, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>TW2Informatics Ltd, Gothenburg</wicri:regionArea><wicri:noRegion>Gothenburg</wicri:noRegion></affiliation></author><author><name sortKey="Spedding, Michael" sort="Spedding, Michael" uniqKey="Spedding M" first="Michael" last="Spedding">Michael Spedding</name><affiliation wicri:level="1"><nlm:affiliation>Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, Le Vesinet, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, Le Vesinet</wicri:regionArea><wicri:noRegion>Le Vesinet</wicri:noRegion><wicri:noRegion>Le Vesinet</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32358833</idno><idno type="pmid">32358833</idno><idno type="doi">10.1111/bph.15094</idno><idno type="pmc">PMC7267163</idno><idno type="wicri:Area/Main/Corpus">001493</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001493</idno><idno type="wicri:Area/Main/Curation">001493</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001493</idno><idno type="wicri:Area/Main/Exploration">001493</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.</title><author><name sortKey="Alexander, Steve P H" sort="Alexander, Steve P H" uniqKey="Alexander S" first="Steve P H" last="Alexander">Steve P H. Alexander</name><affiliation wicri:level="4"><nlm:affiliation>Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), School of Life Sciences, University of Nottingham, Nottingham, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), School of Life Sciences, University of Nottingham, Nottingham</wicri:regionArea><orgName type="university">Université de Nottingham</orgName><placeName><settlement type="city">Nottingham</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Nottinghamshire</region></placeName></affiliation></author><author><name sortKey="Armstrong, Jane F" sort="Armstrong, Jane F" uniqKey="Armstrong J" first="Jane F" last="Armstrong">Jane F. Armstrong</name><affiliation wicri:level="4"><nlm:affiliation>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Davenport, Anthony P" sort="Davenport, Anthony P" uniqKey="Davenport A" first="Anthony P" last="Davenport">Anthony P. Davenport</name><affiliation wicri:level="4"><nlm:affiliation>Executive Committee, NC-IUPHAR, University of Cambridge, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Executive Committee, NC-IUPHAR, University of Cambridge, Cambridge</wicri:regionArea><orgName type="university">Université de Cambridge</orgName><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName></affiliation></author><author><name sortKey="Davies, Jamie A" sort="Davies, Jamie A" uniqKey="Davies J" first="Jamie A" last="Davies">Jamie A. Davies</name><affiliation wicri:level="4"><nlm:affiliation>Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Faccenda, Elena" sort="Faccenda, Elena" uniqKey="Faccenda E" first="Elena" last="Faccenda">Elena Faccenda</name><affiliation wicri:level="4"><nlm:affiliation>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Harding, Simon D" sort="Harding, Simon D" uniqKey="Harding S" first="Simon D" last="Harding">Simon D. Harding</name><affiliation wicri:level="4"><nlm:affiliation>Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Levi Schaffer, Francesca" sort="Levi Schaffer, Francesca" uniqKey="Levi Schaffer F" first="Francesca" last="Levi-Schaffer">Francesca Levi-Schaffer</name><affiliation wicri:level="1"><nlm:affiliation>First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), Hebrew University of Jerusalem, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), Hebrew University of Jerusalem, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Maguire, Janet J" sort="Maguire, Janet J" uniqKey="Maguire J" first="Janet J" last="Maguire">Janet J. Maguire</name><affiliation wicri:level="4"><nlm:affiliation>University of Cambridge, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Cambridge, Cambridge</wicri:regionArea><orgName type="university">Université de Cambridge</orgName><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName></affiliation></author><author><name sortKey="Pawson, Adam J" sort="Pawson, Adam J" uniqKey="Pawson A" first="Adam J" last="Pawson">Adam J. Pawson</name><affiliation wicri:level="4"><nlm:affiliation>Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Southan, Christopher" sort="Southan, Christopher" uniqKey="Southan C" first="Christopher" last="Southan">Christopher Southan</name><affiliation wicri:level="4"><nlm:affiliation>Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>TW2Informatics Ltd, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>TW2Informatics Ltd, Gothenburg</wicri:regionArea><wicri:noRegion>Gothenburg</wicri:noRegion></affiliation></author><author><name sortKey="Spedding, Michael" sort="Spedding, Michael" uniqKey="Spedding M" first="Michael" last="Spedding">Michael Spedding</name><affiliation wicri:level="1"><nlm:affiliation>Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, Le Vesinet, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, Le Vesinet</wicri:regionArea><wicri:noRegion>Le Vesinet</wicri:noRegion><wicri:noRegion>Le Vesinet</wicri:noRegion></affiliation></author></analytic><series><title level="j">British journal of pharmacology</title><idno type="eISSN">1476-5381</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32358833</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br. J. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15094</ELocationID><Abstract><AbstractText>In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.</AbstractText><CopyrightInformation>© 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Steve P H</ForeName><Initials>SPH</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-4417-497X</Identifier><AffiliationInfo><Affiliation>Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), School of Life Sciences, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Jane F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0524-0260</Identifier><AffiliationInfo><Affiliation>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Anthony P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2096-3117</Identifier><AffiliationInfo><Affiliation>Executive Committee, NC-IUPHAR, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Jamie A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6660-4032</Identifier><AffiliationInfo><Affiliation>Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faccenda</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9855-7103</Identifier><AffiliationInfo><Affiliation>Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harding</LastName><ForeName>Simon D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9262-8318</Identifier><AffiliationInfo><Affiliation>Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levi-Schaffer</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0620-2810</Identifier><AffiliationInfo><Affiliation>First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>Janet J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9254-7040</Identifier><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawson</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-2280-845X</Identifier><AffiliationInfo><Affiliation>Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southan</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9580-0446</Identifier><AffiliationInfo><Affiliation>Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TW2Informatics Ltd, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spedding</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1248-8221</Identifier><AffiliationInfo><Affiliation>Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, Le Vesinet, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Award Ref TG/18/4/33770</GrantID><Agency>AF03 British Heart Foundation Translational</Agency><Country></Country></Grant><Grant><GrantID>107715/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32358833</ArticleId><ArticleId IdType="doi">10.1111/bph.15094</ArticleId><ArticleId IdType="pmc">PMC7267163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Pharmacol. 2020 May 1;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32358833</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Israël</li><li>Royaume-Uni</li><li>Suède</li></country><region><li>Angleterre</li><li>Angleterre de l'Est</li><li>Nottinghamshire</li><li>Écosse</li></region><settlement><li>Cambridge</li><li>Nottingham</li><li>Édimbourg</li></settlement><orgName><li>Université d'Édimbourg</li><li>Université de Cambridge</li><li>Université de Nottingham</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Alexander, Steve P H" sort="Alexander, Steve P H" uniqKey="Alexander S" first="Steve P H" last="Alexander">Steve P H. Alexander</name></region><name sortKey="Armstrong, Jane F" sort="Armstrong, Jane F" uniqKey="Armstrong J" first="Jane F" last="Armstrong">Jane F. Armstrong</name><name sortKey="Davenport, Anthony P" sort="Davenport, Anthony P" uniqKey="Davenport A" first="Anthony P" last="Davenport">Anthony P. Davenport</name><name sortKey="Davies, Jamie A" sort="Davies, Jamie A" uniqKey="Davies J" first="Jamie A" last="Davies">Jamie A. Davies</name><name sortKey="Faccenda, Elena" sort="Faccenda, Elena" uniqKey="Faccenda E" first="Elena" last="Faccenda">Elena Faccenda</name><name sortKey="Harding, Simon D" sort="Harding, Simon D" uniqKey="Harding S" first="Simon D" last="Harding">Simon D. Harding</name><name sortKey="Maguire, Janet J" sort="Maguire, Janet J" uniqKey="Maguire J" first="Janet J" last="Maguire">Janet J. Maguire</name><name sortKey="Pawson, Adam J" sort="Pawson, Adam J" uniqKey="Pawson A" first="Adam J" last="Pawson">Adam J. Pawson</name><name sortKey="Southan, Christopher" sort="Southan, Christopher" uniqKey="Southan C" first="Christopher" last="Southan">Christopher Southan</name></country><country name="Israël"><noRegion><name sortKey="Levi Schaffer, Francesca" sort="Levi Schaffer, Francesca" uniqKey="Levi Schaffer F" first="Francesca" last="Levi-Schaffer">Francesca Levi-Schaffer</name></noRegion></country><country name="Suède"><noRegion><name sortKey="Southan, Christopher" sort="Southan, Christopher" uniqKey="Southan C" first="Christopher" last="Southan">Christopher Southan</name></noRegion></country><country name="France"><noRegion><name sortKey="Spedding, Michael" sort="Spedding, Michael" uniqKey="Spedding M" first="Michael" last="Spedding">Michael Spedding</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001812 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001812 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32358833
|texte= A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32358833" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |